Readystate Asset Management LP Buys New Stake in DexCom, Inc. (NASDAQ:DXCM)

Readystate Asset Management LP bought a new stake in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 40,270 shares of the medical device company’s stock, valued at approximately $4,997,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Bartlett & CO. Wealth Management LLC bought a new stake in DexCom in the 4th quarter valued at $27,000. DSM Capital Partners LLC bought a new stake in DexCom in the 4th quarter valued at $28,000. Valley National Advisers Inc. boosted its holdings in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Harbour Investments Inc. boosted its holdings in DexCom by 55.6% in the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 120 shares during the period. Finally, Atlas Capital Advisors LLC bought a new stake in DexCom in the 2nd quarter valued at $33,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares in the company, valued at approximately $44,479,027.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the sale, the chief executive officer now owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DexCom stock traded down $2.66 during mid-day trading on Wednesday, reaching $133.86. 3,222,232 shares of the stock were exchanged, compared to its average volume of 2,995,804. The company has a market cap of $51.61 billion, a price-to-earnings ratio of 102.18, a price-to-earnings-growth ratio of 2.31 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a 50-day simple moving average of $129.20 and a 200 day simple moving average of $116.28. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same quarter last year, the company posted $0.34 EPS. On average, sell-side analysts predict that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

DXCM has been the subject of a number of research reports. UBS Group increased their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Raymond James increased their price target on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price objective for the company. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Piper Sandler raised their price objective on shares of DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $141.40.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.